Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Accumulated Expenses (2020 - 2025)

Rapid Micro Biosystems' Accumulated Expenses history spans 6 years, with the latest figure at $8.3 million for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 15.23% to $8.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.3 million, a 15.23% increase, with the full-year FY2025 number at $8.3 million, up 15.23% from a year prior.
  • Accumulated Expenses hit $8.3 million in Q4 2025 for Rapid Micro Biosystems, up from $6.6 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for RPID hit a ceiling of $11.6 million in Q3 2021 and a floor of $935000.0 in Q2 2022.
  • Historically, Accumulated Expenses has averaged $6.8 million across 5 years, with a median of $7.0 million in 2024.
  • Biggest five-year swings in Accumulated Expenses: plummeted 52.17% in 2022 and later surged 721.93% in 2023.
  • Tracing RPID's Accumulated Expenses over 5 years: stood at $10.9 million in 2021, then fell by 25.35% to $8.2 million in 2022, then grew by 21.56% to $9.9 million in 2023, then fell by 27.15% to $7.2 million in 2024, then grew by 15.23% to $8.3 million in 2025.
  • Business Quant data shows Accumulated Expenses for RPID at $8.3 million in Q4 2025, $6.6 million in Q3 2025, and $5.7 million in Q2 2025.